Who knows the assignment and why it matters
Single-blind trials withhold treatment assignment from participants but not assessors; participants don't know if they received active treatment or placebo, reducing expectancy bias. Double-blind trials keep both participants and assessors blinded, further reducing bias from assessor behavior or subjective judgment. Triple-blind adds independent data analysts, though this level is rare.
Each blinding layer prevents a different bias: unblinded participants may report improvement from expectation alone (placebo response), unblinded assessors may interpret ambiguous outcomes favorably toward a preferred treatment, and unblinded analysts might make favorable choices in borderline analytic decisions. Stacking protections is cumulative.
Practical limitations of blinding in real trials
Some interventions resist blinding. Surgery, behavioral therapy, and certain drugs with distinctive side effects cannot be hidden from participants. In these cases, researchers use sham surgery, attention-matched controls, or rater-blinding on objective endpoints (instead of subjective symptom scores). Acknowledging blinding limitations honestly is crucial for interpreting trial results.
Open-label designs (no blinding) are acceptable for objective outcomes (mortality, hospitalization) but risky for subjective ones (pain, fatigue). A trial showing treatment superiority on subjective measures in unblinded design raises concern that expectations, not intervention, drove the difference. Blinding quality is a key piece of risk-of-bias assessment.